Using neural biomarkers to personalize dosing of vagus nerve stimulation.

Antonin Berthon¹, Lorenz Wernisch², Myrta Stoukidi², Michael Thornton², Olivier Tessier-Lariviere², Pascal Fortier-Poisson², Jorin Mamen², Max Pinkney², Susannah Lee², Elvijs Sarkans², Luca Annecchino², Ben Appleton², Philip Garsed², Bret Patterson², Samuel Gonshaw², Matjaz Jakopec², Sudhakaran Shunmugam², Tristan Edwards², Aleksi Tukiainen², Joel Jennings², Guillaume Lajoie³, Emil Hewage², Oliver Armitage²

¹BIOS Health Ltd., Cambridge, UK. berthon.antonin@gmail.com.

²BIOS Health Ltd., Cambridge, UK.

³Université de Montréal and Mila-Quebec AI Institute, Montréal, Canada.

PubMed PMC DOI PDF

Abstract

BACKGROUND: Vagus nerve stimulation (VNS) is an established therapy for treating a variety of chronic diseases, such as epilepsy, depression, obesity, and for stroke rehabilitation. However, lack of precision and side-effects have hindered its efficacy and extension to new conditions. Achieving a better understanding of the relationship between VNS parameters and neural and physiological responses…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.